in black and white
Main menu
Share a book About us Home
Biology Business Chemistry Computers Culture Economics Fiction Games Guide History Management Mathematical Medicine Mental Fitnes Physics Psychology Scince Sport Technics

biopharmaceuticals biochemistry and biotecnology - Walsh G.

Walsh G. biopharmaceuticals biochemistry and biotecnology - John Wiley & Sons, 2003. - 572 p.
ISBN 0-470-84327-6
Download (direct link): biochemistryandbiotechnology2003.pdf
Previous << 1 .. 145 146 147 148 149 150 < 151 > 152 153 154 155 156 157 .. 292 >> Next

Additional cytokines (IL-3, IL-6, IL-11 and LIF) also promote a proliferative response in megakaryocytes. Although these exhibit some ability to increase platelet levels, the physiological significance of this remains unclear. TPO, on the other hand, induces a far swifter, greater and more specific response. In one study, its administration to mice over a period of 6 days resulted in a four-fold increase in platelet count (although some other studies reported a less pronounced effect). Furthermore, TPO administration to animals whose platelet production had been severely compromised by radio- or chemotherapy accelerated subsequent recovery of platelet numbers to normal values. The future clinical outlook for this haemopoietic growth factor looks bright.
Dallman, M. (2000). Haemapoietic and Lymphoid Cell Culture. Cambridge University Press, Cambridge.
Kuter, D. et al. (Eds) (1997). Thrombopoiesis and Thrombopoietins. Humana, Totowa, NJ, USA.
Medkalf, D. (1995) Haemopoietic Colony-stimulating Factors: From Biology to Clinical Applications. Cambridge University Press, Cambridge.
Morstyn, G. (1998). Filgrastim in Clinical Practice. Marcel Dekker, New York.
Orlic, D. (1999). Haematopoietic Stem Cells. New York Academy of Science, New York.
Erythropoietin and thrombopoietin
Basser, R. (2002). The impact of thrombopoietin on clinical practice. Curr. Pharmaceut. Design 8(5), 369-377.
Bottomley, A. et al. (2002). Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol. 3(3), 145-153.
Buemi, M. et al. (2002). Recombinant human erythropoietin: more than just the correction of uremic anemia. J. Nephrol. 15(2), 97-103.
Fried, W. (1995). Erythropoietin. Ann. Rev. Nutrit. 15, 353-377.
Geddis, A. et al. (2002). Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev. 13(1), 61-73.
Kaushansky, K. (1995). Thrombopoietin: the primary regulator of platelet production. Blood 86(2), 419-431.
Kaushansky, K. (1997). Thrombopoietin—understanding and manipulating platelet production. Annu. Rev. Med. 48, 1-11.
Kaushansky, K. & Drachman, J. (2002). The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 21(21), 3359-3367.
Kendall, R. (2001). Erythropoietin. Clin. Lab. Haematol. 23(2), 71-80.
Lok, S. et al. (1994). Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369, 565-568.
Markham, A. & Bryson, H. (1995). Epoetin Alfa, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in non-renal applications. Drugs 49(2), 232-254.
Metcalf, D. (1994). Thrombopoietin—at last. Nature 369, 519-520.
Miyazaki, H. & Kato, T. (1999). Thrombopoietin: biology and clinical potential. Int. J. Haematol. 70(4), 216-225. Ogden, J. (1994). Thrombopoietin—the erythropoietin of platelets? Trends Biotechnol. 12, 389-390.
Roberts, D. & Smith, D. (1994). Erythropoietin: induction of synthesis to signal transduction. J. Mol. Endocrinol. 12, 131-148.
Spivak, J. (1994). Recombinant human erythropoietin and the anaemia of cancer. Blood 84(4), 997-1004.
Cheetham, J.C., Smith, D.M., Aoki, K.H. et al. (1998). NMR structure of human erythropoietin and a comparison with its receptor-bound conformation. Nature Struct. Biol. 5, 861.
Dranoff, G. et al. (1994). Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264, 713-715.
Duarte, R. & Frank, D. (2002). The synergy between stem cell factor (SCF) and granulocyte colony stimulating factor (G-CSF): molecular basis and clinical relevance. Leukaemia Lymphoma 43(6), 1179-1187.
Frampton, J. et al. (1994). Filgrastim, a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 48(5), 731-760.
Frampton, J. et al. (1995). Lenograstim, a review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 49(5), 767-793.
Hamilton, J. (1997). CSF-1 signal transduction. J. Leukocyte Biol. 62(2), 145-155.
Harousseau, J. (1997). The role of colony-stimulating factors in the treatment of acute leukaemia. Biodrugs 7(6), 448-460.
Spangrude, G. (1994). Biological and clinical aspects of haematopoietic stem cells. Ann. Rev. Med. 45, 93-104. Tabbara, I. et al. (1996). The clinical applications of granulocyte-colony-stimulating factor in haematopoietic stem cell transplantation — a review. Anticancer Res. 16(6B), 3901-3905.
Walter, M.R., Cook, W.J., Ealick, S.E. et al. (1992). Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor. J. Mol. Ecol. 224, 1075.
Watowich, F. et al. (1996). Cytokine receptor signal transduction and the control of haematopoietic cell development. Ann. Rev. Cell Dev. Biol. 12, 91-128.
Chapter 7 Growth factors
Previous << 1 .. 145 146 147 148 149 150 < 151 > 152 153 154 155 156 157 .. 292 >> Next